Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2020

View Archived Issues

Glial metabolism affects neural recovery

Kemp Proteins to provide assay development for first-in-class chronic SCI therapy, AXER-204

Genentech and Roche divulge new antibacterials

Gilead Sciences presents new PKC agonists

First-in-human study of IGM-8444 begins in patients with solid tumors

AbbVie and Galapagos identify CFTR mutant correctors

New potential broad-spectrum fungicides discovered

Phase I data for sotorasib in advanced solid tumors harboring the KRAS p.G12C mutation

Researchers develop mouse-adapted SARS-CoV-2 model causing age-related disease pathogenesis

Cyteir Therapeutics describes RAD51A inhibitors

REVOLUTION Medicines patents SOS1 inhibitors

P2X4R inhibition reduces proinflammatory myeloid cells, offering neuroprotection after stroke

First clinical data presented for first-in-class NOTCH inhibitor CB-103

Henlius reports phase III data on bevacizumab biosimilar HLX-04

First-in-human study evaluates AZD-8701 alone and with durvalumab in advanced solid tumors

Debio-1143 studied in phase III with chemoradiotherapy for locally advanced SCCHN

M-8891 has manageable safety profile and favorable PK in first-in-human study

ILT4 antibody MK-4830 well tolerated, shows encouraging responses in phase I study

First-in-human data presented for TLD-1

Micreos begins phase I/IIa study of endolysin XZ.700 in atopic dermatitis

Durect eyes initiation of phase IIb trial of DUR-928 in alcoholic hepatitis

Vaccinex reports topline phase II data on pepinemab in Huntington's disease

FDA accepts IND for adoptive T-cell therapy GEN-011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...